The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, shares early findings from the Phase I/II TITANium trial (NCT06542250), which is evaluating AZD5492, a novel bispecific antibody, in patients with relapsed/refractory (R/R) B-cell malignancies. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
TITANium is a very interesting study that’s been sponsored by AstraZeneca, where the goal of this is to look at a new bispecific antibody, in this case with CD8 targeting on the T-cell as well as targeting CD20. So the goal here was to take advantage of potentially more favorable toxicity by potentially not targeting all CD3 positive T-cells. And again, using one of the typical cell surface antigens we use well in aggressive lymphoma and indolent lymphoma is CD20...
TITANium is a very interesting study that’s been sponsored by AstraZeneca, where the goal of this is to look at a new bispecific antibody, in this case with CD8 targeting on the T-cell as well as targeting CD20. So the goal here was to take advantage of potentially more favorable toxicity by potentially not targeting all CD3 positive T-cells. And again, using one of the typical cell surface antigens we use well in aggressive lymphoma and indolent lymphoma is CD20. The preliminary results today, again, speak to safety fundamentally. So thankfully, we’re not seeing any concerning signs there. And again, now starting to see some good signs of efficacy as patients continue to be enrolled onto the study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
